Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

QR-010

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by ProQR Therapeutics

Phase 1/2 Most advanced trial (none active)

PRQR Developer

1 Registered trials

What is QR-010?

QR-010 is a single-stranded RNA antisense oligonucleotide administered by oral inhalation. It is being studied in cystic fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Mechanism: Gene silencing
Therapy area: Respiratory
Developer: ProQR Therapeutics (PRQR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: V30WFP6S2Y

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02532764	Phase 1/2	Cystic Fibrosis	Completed	PRQR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis

More from ProQR Therapeutics

QR-1123 Phase 1/2 QR-421a Phase 1/2 QR-504a Phase 1 Sepofarsen Phase 2/3

Sources

ClinicalTrials.gov NCT02532764

Updated Oct 3, 2026. Something wrong or missing? Report it on the PRQR page.

Follow PRQR, the company behind QR-010

See PRQR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRQR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z